A 3-month open-label trial investigated the weight loss and glycemic control effects of benaglutide in patients with T2DM
Until they are, this page states only what was measured and in whom
3,5 Pfizer also announced the development of danuglipron
Monitoring Progress: Weight, Appetite and Clinical Markers Progress is monitored through regular weight measurements, appetite assessments, and metabolic markers including HbA1c, lipid profile, blood pressure, and waist circumference, with clinical reviews every four to twelve weeks initially
There is no penalty for going slower
Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders